Elanco Animal Health (ELAN)vsHaleon plc (HLN)
ELAN
Elanco Animal Health
$26.39
+3.41%
HEALTHCARE · Cap: $12.90B
HLN
Haleon plc
$10.28
+0.10%
HEALTHCARE · Cap: $43.07B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 125% more annual revenue ($11.03B vs $4.89B). HLN leads profitability with a 15.1% profit margin vs -5.0%. HLN appears more attractively valued with a PEG of 2.58. HLN earns a higher WallStSmart Score of 63/100 (C+).
ELAN
Hold44
out of 100
Grade: D
HLN
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-32.5%
Fair Value
$19.41
Current Price
$26.39
$6.98 premium
Intrinsic value data unavailable for HLN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 92.0% YoY
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Areas to Watch
Expensive relative to growth rate
ROE of -3.7% — below average capital efficiency
Earnings declined 15.4%
Negative free cash flow — burning cash
0.6% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ELAN
The strongest argument for ELAN centers on Price/Book. Revenue growth of 14.9% demonstrates continued momentum.
Bull Case : HLN
The strongest argument for HLN centers on EPS Growth, Price/Book, Operating Margin. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bear Case : ELAN
The primary concerns for ELAN are PEG Ratio, Return on Equity, EPS Growth.
Bear Case : HLN
The primary concerns for HLN are Revenue Growth, Altman Z-Score, PEG Ratio.
Key Dynamics to Monitor
ELAN profiles as a turnaround stock while HLN is a value play — different risk/reward profiles.
ELAN carries more volatility with a beta of 1.69 — expect wider price swings.
ELAN is growing revenue faster at 14.9% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (63/100 vs 44/100), backed by strong 15.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elanco Animal Health
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets products for pets and farm animals. The company is headquartered in Greenfield, Indiana.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?